# A Phase Ⅱ Study of an All-Oral Combination of Low-dose Etoposide/Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and/or Taxanes

> **NCT01589159** · PHASE2 · COMPLETED · sponsor: **Tao OUYANG** · enrollment: 54 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** Etoposide

## Key facts

- **NCT ID:** NCT01589159
- **Lead sponsor:** Tao OUYANG
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2016-07
- **Final completion:** 2016-12
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2017-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01589159

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01589159, "A Phase Ⅱ Study of an All-Oral Combination of Low-dose Etoposide/Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and/or Taxanes". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01589159. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*